Insurance, affordability, FDA approvals, access, health policy, and cost-related IBD news.
Page 2 of 7 · 316 articles
A new Phase 2 study of StemSmart™ could expand treatment options for patients with refractory or fistulising Crohn’s disease if later trials confirm safety and benefit. Appointment of a CRO is an early but important step...
Many reproductive-aged women with IBD and other autoimmune conditions may not have documented claims for prescription or permanent contraception, including women taking medications with potential fetal risks. That gap...
A dedicated Digestive Health Centre could make it easier for people with IBD (including children and teens) to access coordinated care—fewer separate visits and more centralized specialist services in one location.
Cure8 could only read part of this source from manilatimes.net, so this card uses cautious topic tags instead of a full summary. It is tagged for Access, cost, and policy.
New Phase II trials test whether a gut-activated oral PDE4 inhibitor can treat moderate-to-severe ulcerative colitis and Crohn’s while avoiding systemic PDE4 tolerability issues; positive Phase II results could add a new...
Diet and meal preparation can affect comfort and symptom management for many people with IBD. Free, curated recipe tools make it easier to find meals suited to sensitive digestive tracts without trial-and-error.
Scholarships and peer communities can ease the financial and emotional burden of living with IBD and help students find supportive networks and career inspiration. Stories like these highlight practical resources and the...
A protein bar marketed for digestibility may appeal to people with Crohn’s, ulcerative colitis, or other IBD-related digestive sensitivity who struggle to find convenient, protein-rich snacks. The company’s community...
Trial design affects how quickly and reliably new IBD treatments are tested and approved, and can influence patient experience (placebo exposure, retention) and whether trial populations reflect real-world patients.
Regulatory approvals and trial activity for upadacitinib (Rinvoq) affect availability and prescribing patterns for immunomodulatory treatment options used across autoimmune and inflammatory diseases, including IBD.
Biologics can be critical for treating moderate-to-severe IBD, but cost and treatment failure limit access and long‑term use in this Indian cohort. Understanding uptake and reasons for stopping helps target interventions...
Crohn’s disease prevalence and new diagnoses are rising rapidly in Korea, especially among people in their 20s and 30s; that affects demand for diagnosis, long-term care, and affordable treatment.
Delays and incomplete pre-referral screening are common in pediatric IBD and can affect how sick children are when they first see specialists. Better, standardized use of fecal calprotectin and abdominal ultrasound...
This large national-registry study identifies clinical features linked with needing optimization of biologic or small-molecule therapies in CD and UC. That helps show which patient groups more often require...
Financial barriers are common among US adults with IBD and are linked to delayed care and skipping medications — problems that can worsen disease control and quality of life.
Cure8 found this source from crohnscolitisfoundation.org, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Access, cost, and policy. Open the original article...
Stopping Crohn's medications can cause flares and serious complications, and restarting treatment may be slower or less effective. Adherence and financial or practical support can help prevent these harms.
Treating fibrotic strictures would address an unmet need in Crohn’s disease — current approved drugs target inflammation, not established fibrosis. Positive Phase 2a signals could eventually lead to a new pharmacologic...
Young people with IBD often struggle with health insurance knowledge during transition to adult care. Improving insurance literacy can help them access care and manage coverage decisions. This study suggests a brief,...
Shifting to patient-initiated, digitally supported follow-up could maintain disease control while reducing routine fixed-interval visits and improving patient experience — relevant as IBD patient numbers grow and clinic...
Defining whether IBD therapies prevent long-term damage matters to patients and clinicians because it affects treatment goals and long-term care planning.
Surgeons and other clinicians managing IBD patients need to understand current biologic and immunomodulator options, their risks, and implications for surgical timing and perioperative care.
Family history of CRC raises an individual’s absolute CRC risk whether or not they have IBD, and people with IBD who have multiple first‑degree relatives with CRC appear to have the largest increase in absolute risk....
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
Older adults (≥60) with IBD are an increasing population worldwide, and IBD-related anemia is rising—this affects screening needs, healthcare planning, and resource allocation. The findings point to widening...
Patients cared for in accredited IBD units reported better experience and higher satisfaction in this study, which suggests that accreditation may improve patient-centred aspects of care even if self-reported disease...
The findings highlight that older adults are less likely to be prescribed advanced IBD therapies, which could reflect prescribing patterns, comorbidities, insurance factors, or access issues relevant to treatment...
Clinical trials test new treatments that could become options for people with moderate to severe Crohn’s disease. This sponsor-supported notice also highlights the need for broader representation in research, which...
This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...
Coordinated transition to adult gastroenterology affects continuity of care for children with chronic GI conditions such as IBD; improvements could reduce gaps in treatment and support during young adulthood.
Antibiotic use patterns in hospitalized IBD patients affect infection risks, microbiome impact, resistance pressure, length of stay, and costs. Shifting focus from simple exposure counts to intensity and escalation can...
Cure8 could only read part of this source from benefitspro.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Biosimilars and Access, cost, and policy.
This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...
Based on the title and source metadata, this appears to be a market or business news related to Access, cost, and policy. The original article is from firstwordpharma.com.
Many people with IBD change their diets and avoid foods they believe trigger flares. Differences between Crohn’s disease and ulcerative colitis were observed, and many—especially those with UC—reported not receiving...
Many pediatric patients with IBD receive infusion biologic therapies. Shifts in where those infusions happen (driven by payer policies) can create administrative burdens and raise concerns about safety and care...
This gives families and clinicians a non‑TNF biologic option on‑label for children aged 2+ with moderate‑to‑severe ulcerative colitis, which can change insurance conversations and expand treatment choices for kids who...
Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.
This study looks at how immunomodulators are actually used with biologic drugs in real-world practice when a national reimbursement policy forces biologic interruptions.
This large, population-level analysis summarizes long-term global trends in IBD burden and shows rising incidence and persistent geographic and socio-demographic inequalities. Patients and clinicians may see why...
Clinical trials shape available treatments and evidence; if groups of children (by race, ethnicity, or sex) are underrepresented, study results may not reflect how treatments work for them. This paper identifies...
A new subcutaneous induction option for risankizumab could make starting this biologic easier for many adults with moderate-to-severe Crohn's disease by avoiding infusions, potentially increasing access and convenience.
Black women with Crohn’s may face higher risk of delayed diagnosis, hospitalization, surgery, and complications such as abscesses, infertility, and bone loss — issues that affect treatment choices and quality of life.
Fundraisers like this support research, patient programs, and advocacy that can expand resources and advance scientific work relevant to people with Crohn’s disease and ulcerative colitis.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from tradingview.com.
A subcutaneous induction option could make starting risankizumab easier and less burdensome than IV infusions for many people with Crohn's disease, potentially expanding access and convenience.
A new subcutaneous induction option for risankizumab could make starting IL‑23 therapy more convenient for adults with moderately to severely active Crohn’s disease and expand choices for those who have failed prior...
If approved, a subcutaneous induction option for risankizumab would let eligible adults start and continue treatment without needing an infusion visit, which can be more convenient and reduce infusion-related costs and...
